CUNDE

Sichuan Cunde Therapeutics Co., Ltd. (hereinafter referred to as "the Company") was established on November 7, 2016, and is located in the High-Tech Zone of Chengdu City. The Company was initiated by Chongqing Lummy Pharmaceutical Co., Ltd. (hereinafter referred to as "Lummy Pharmaceuticals," stock code: 300006). Its core team consists of multiple returned overseas elites. By integrating the advantageous resources of three listed biopharmaceutical companies from China, the United States, and Russia, and leveraging the strong scientific research capabilities of well-known universities at home and abroad, the Company focuses on the research, diagnosis, treatment, and services for major diseases such as cancer. The Company is mainly dedicated to the technological transformation, secondary development, application, and promotion in China of innovative technologies such as precision analysis based on tumor-specific gene mutations and tumor immunotherapy. Based on the individualized specific tumor antigens of patients, the Company applies immunological principles and methods to enhance the immune system's recognition of tumor cells, increase the immunogenicity of tumor cells and their sensitivity to effector cell killing, stimulate and strengthen the body's anti-tumor immune response, and infuse the reconstructed immune cells and effector molecules into the host to synergize with the body's immune system in killing tumors, inhibiting tumor growth, and reducing tumor recurrence.In 2015, the Company introduced the internationally advanced multifunctional cell therapy platform "Arcelis® Technology Platform." The Company’s product CUD-002 is the latest generation product independently developed using this technology platform, primarily used for patients with advanced ovarian cancer and liver cancer. By incorporating high-throughput gene sequencing technology and artificial synthesis technology of tumor-specific antigens, the platform enhances target specificity, improves tumor-killing effects, and reduces side effects.